The Republic of Mali has taken a bold step in the fight against malaria by rolling out the R21/Matrix-M vaccine, endorsed by the World Health Organization (WHO). In the regions of Kayes and Mopti, this groundbreaking immunization strategy is already shielding thousands of Mali’s youngest citizens from the deadly disease.

With backing from the WHO, Gavi, and UNICEF, Mali has woven the R21/Matrix-M antimalarial vaccine into its Expanded Programme on Immunization (EPI). This initiative targets 19 high-risk districts across five regions, with Kayes and Mopti at the forefront. The approach leverages innovative tactics to ensure robust protection before malaria’s peak transmission season.

Hybrid strategy: A dual-layered defense

Unlike traditional vaccines, Mali’s deployment follows a hybrid strategy designed for peak efficacy. Here’s how it works:

• Age-based dosing: Ensures infants develop foundational immunity early.
• Seasonal reinforcement: Vaccine doses are timed to roll out just before the rainy season, when mosquito activity—and malaria risks—peak.

Kayes and Mopti: Pioneering districts in malaria control

Kayes and Mopti were selected as pilot zones due to their persistent malaria burden. These districts serve as real-world testing grounds for the vaccine’s effectiveness under field conditions.

In Mopti, despite logistical hurdles, seamless coordination among health services and partners enabled smooth vaccine distribution. Meanwhile, in Kayes, community mobilization has been key to ensuring timely booster doses—critical for long-term protection.

A complementary shield, not a standalone fix

Health authorities emphasize that the R21/Matrix-M vaccine is one critical tool among many in Mali’s malaria arsenal. It works alongside proven prevention methods, including:

• Long-lasting insecticidal nets (LLINs): Essential for nighttime protection.
• Seasonal malaria chemoprevention (SMC): The vaccine enhances the impact of preventive antimalarial drugs.

Reducing child mortality through innovation

The vaccine’s primary goal is to slash malaria-related deaths among children under five, the most vulnerable group. Success in Kayes and Mopti could pave the way for national expansion, marking a turning point in Mali’s public health journey.